Carpmaels adds further patent litigators

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Carpmaels adds further patent litigators

balleny-camilla-55.jpg

UK IP firm Carpmaels & Ransford has enhanced its recently launched litigation practice with the hire of Camilla Balleny from Pinsent Masons

Balleny

Balleny (right), a life science specialist, joins as a partner and brings with her Lucy Sewter, a legal executive.

The firm acts for big pharma companies including Novartis and Johnson & Johnson, as well as growing companies such as Gilead, Shire and Vertex.

The appointment comes after the firm recently launched an IP litigation practice with the hiring of Ian Kirby and Jonathan Day from Arnold & Porter. It is one of several patent attorney firms to develop integrated practices ahead of the launch of the Unitary Patent and Unified Patent Court.

Balleny has been a partner of Pinsent Masons for four years, and was previously at Arnold & Porter. Sewter led the IP litigation support team at Pinsent Masons.

more from across site and SHARED ros bottom lb

More from across our site

Tristan Sherliker says he hopes to solve an access to justice issue by making the automated court bundle tool free to use
The team, comprising two partners and one senior consultant, plans to offer “highly differentiated” services to clients
HGF’s new ownership model frees it from the hiring constraints of traditional partnerships, its CEO told Managing IP
New timeline for 2026 aims to provide clearer guidance to firms and practitioners on the full jurisdictional market view
Attorneys contemplate whether clients using AI for legal guidance is beneficial to attorney-client relationships or more of a nuisance
Richard de Bodo, who had a lengthy career at international firms, shares how he will address client needs and praises the unique offerings of smaller firms
An Australian top court decision clarifying honest concurrent use and wins by publishers against AI platforms were also among the top talking points
AIPPI has pulled the plug on its planned 2027 World Congress, and INTA has delayed hosting a meeting there, but the concerns won’t abate
Despite being outspent by a wealthy opponent, a trial attorney at King & Spalding says ‘relentless pursuit of the truth’ helped his team secure a $420m damages award for mobile gaming client
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Gift this article